HUTCHMED (China) Ltd (HCM)
HUTCHMED (China) Ltd (HCM) from its SEC filings: 2025 revenue $548.5 million (-13% vs the year before), net margin 83%, free cash flow -$78.8 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $548.5 million |
| Revenue growth | -13% |
| Net income | $456.9 million |
| Net margin | 83.3% |
| Free cash flow | -$78.8 million |
| Diluted EPS | $0.52 |
| Latest quarter (Q1 2019 (calendar)) revenue vs a year earlier | -0% |
| Cash | $71.3 million |
| Long-term debt | $68.2 million |
| Share count, 1 year | +0% |
| Fundamentals check | Mixed fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.